Nathalie L.G. Sieben

In ovarian neoplasms, <i>BRAF</i> , but not <i>KRAS</i> , mutations are restricted to low‐grade serous tumours

Nathalie L.G. Sieben, Patricia Macropoulos, Guido M.J.M. Roemen et al. · The Journal of Pathology · 2004 · 236 citations

PCR artifacts in LOH and MSI analysis of microdissected tumor cells

Nathalie L.G. Sieben, Natalja T. ter Haar, Cees J. Cornelisse et al. · Human Pathology · 2000 · 91 citations

Microdissected Tumor Cells, Tumor Biology, Cancer Detection +11

Differential Gene Expression in Ovarian Tumors Reveals <i>Dusp 4</i> and <i>Serpina 5</i> As Key Regulators for Benign Behavior of Serous Borderline Tumors

Nathalie L.G. Sieben, Jan Oosting, Adrienne M. Flanagan et al. · Journal of Clinical Oncology · 2005 · 88 citations

Molecular Genetic Evidence for Monoclonal Origin of Bilateral Ovarian Serous Borderline Tumors

Nathalie L.G. Sieben, Sandra Kolkman-Uljee, Adrienne M. Flanagan et al. · American Journal Of Pathology · 2003 · 49 citations · Full text

Tumor Heterogeneity, Medicine, Molecular Genetic Evidence +7

Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors

Ingrid T.G.W. Bijsmans, Kim M. Smits, Pauline de Graeff et al. · Modern Pathology · 2010 · 42 citations · Full text

Medicine, Serpina5 Protein Expression, Pathology +6